Recombinant Human EMAP-II

Recombinant Human EMAP-II is a multifunctional cytokine with significant roles in angiogenesis inhibition, inflammation, apoptosis, and tumor biology, making it a valuable tool for diverse research applications in cancer, immunology, and vascular biology.

Key scientific reasons to use recombinant human EMAP-II in research include:

• Antiangiogenic and Antitumor Activity: EMAP-II inhibits endothelial cell proliferation, vasculogenesis, and neovessel formation, thereby suppressing the growth of primary and metastatic tumors without affecting normal tissues. It induces apoptosis in proliferating and hypoxic endothelial cells, contributing to its antiangiogenic effects.

• Modulation of Tumor Microenvironment: EMAP-II sensitizes tumor-associated vasculature to tumor necrosis factor (TNF-α), enhancing the efficacy of TNF-based therapies and modulating the tumor response to inflammation. It also increases the permeability of the blood-tumor barrier, which can facilitate drug delivery to tumors.

• Proinflammatory and Chemotactic Properties: EMAP-II acts as a chemoattractant for monocytes and granulocytes, and increases the adhesiveness of vascular smooth muscle cells for monocytes, making it useful for studying inflammatory cell recruitment and vascular inflammation.

• Induction of Apoptosis: EMAP-II induces apoptosis in endothelial cells and tumor cells, which is relevant for research into cell death mechanisms, tumor regression, and the regulation of angiogenesis.

• Biomarker Potential: Elevated EMAP-II levels have been associated with poor prognosis in certain cancers, such as non-small cell lung cancer, suggesting its utility as a biomarker for disease progression and therapeutic response.

• Hypoxia and Immune Evasion Studies: EMAP-II is upregulated under hypoxic conditions and can mediate lymphocyte apoptosis, contributing to tumor immune evasion. This makes it a useful reagent for investigating hypoxia-driven changes in the tumor microenvironment and immune cell dynamics.

• Versatile Experimental Applications: Recombinant EMAP-II can be used in cell culture assays, animal models, and biochemical studies to dissect its molecular mechanisms, test therapeutic strategies, and develop neutralizing antibodies for functional studies.

In summary, recombinant human EMAP-II is a critical reagent for mechanistic studies of angiogenesis, inflammation, apoptosis, and tumor biology, and for developing novel therapeutic approaches targeting the tumor microenvironment and immune response.

Recombinant Human EMAP-II can be used as a standard for quantification or calibration in ELISA assays, provided the assay antibodies recognize the recombinant form equivalently to the native protein. This is a common practice in ELISA development and validation, but several technical considerations must be addressed to ensure accurate quantification.

Key considerations and best practices:

• Standard Curve Preparation: Recombinant proteins are routinely used to generate standard curves in ELISA assays when purified native protein is unavailable. The recombinant EMAP-II should be well-characterized, with known concentration and purity, and reconstituted according to manufacturer or laboratory instructions.

• Antibody Recognition: The critical requirement is that the ELISA antibodies (capture and detection) bind the recombinant EMAP-II with similar affinity and specificity as the endogenous (native) protein. Differences in post-translational modifications or folding between recombinant and native EMAP-II can affect antibody binding and quantification accuracy.

• Validation Steps:

  • Parallelism: Validate that serial dilutions of biological samples containing endogenous EMAP-II yield curves parallel to those generated with recombinant standards. This confirms comparable antibody recognition and quantification.
  • Dilution Linearity: Spike biological samples with recombinant EMAP-II and confirm recovery across the standard curve range.
  • Matrix Effects: Test for interference from sample matrices (e.g., serum, plasma, tissue lysates) by spiking known amounts of recombinant EMAP-II into these matrices and assessing recovery.

• Calibration Reference: For harmonized quantification, calibrate recombinant standards against international reference materials (e.g., NIBSC/WHO standards) if available.

• Documentation: Clearly document the source, lot, and characterization of the recombinant EMAP-II used as a standard, as this affects reproducibility and comparability across experiments.

Limitations:

• Some commercial ELISA kits are validated only for native EMAP-II and may not guarantee equivalent detection of recombinant forms. Always consult the kit documentation and, if necessary, perform in-house validation using recombinant standards.

Summary Table: Recombinant EMAP-II as ELISA Standard

In conclusion, recombinant Human EMAP-II is suitable as a standard for ELISA quantification if the above validation steps are followed to ensure assay accuracy and reliability.

Recombinant Human EMAP-II has been validated in published research for several key applications, primarily in studies of inflammation, apoptosis, angiogenesis, and vascular biology.

Key validated applications include:

• Induction of apoptosis in endothelial and tumor cells: Recombinant EMAP-II has been used to demonstrate its ability to induce apoptosis in proliferating and hypoxic endothelial cells, as well as in tumor cells, both in vitro and in vivo.
• Chemotaxis and activation of immune cells: It has been applied to study the migration and activation of monocytes and neutrophils, showing chemotactic properties and the ability to activate these immune cells.
• Anti-angiogenic assays: EMAP-II has been validated as an anti-angiogenic factor, inhibiting endothelial cell proliferation, vasculogenesis, and neovessel formation, particularly in tumor vascular development models.
• Western blot and ELISA detection: Recombinant EMAP-II is used as a standard or antigen in Western blotting and ELISA assays to detect EMAP-II protein or to validate antibody specificity.
• Disease model studies: It has been used in animal models to study its role in inflammatory conditions, tumor angiogenesis, pulmonary hypertension, and hypoxia-induced vascular remodeling.
• Functional blocking and neutralization studies: Recombinant EMAP-II is used to test the efficacy of neutralizing antibodies or inhibitors targeting EMAP-II-mediated biological effects, such as monocyte migration and apoptosis.

Additional details:

• Molecular and cellular assays: EMAP-II is used in in vitro assays to study its effects on gene expression, cell signaling, and cytokine production in endothelial and immune cells.
• Biomarker studies: Its expression and functional effects are investigated as potential biomarkers in disease models, especially in the context of inflammation and cancer.

These applications are supported by multiple peer-reviewed studies and are central to understanding the biological and pathological roles of EMAP-II in human disease.

Reconstitution Protocol

Initial Preparation

Begin by centrifuging the lyophilized vial briefly at room temperature to concentrate the powder at the bottom of the tube. This step ensures you recover all the protein material and facilitates even reconstitution. Allow both the vial and reconstitution buffer to equilibrate to room temperature before proceeding.

Reconstitution Procedure

Reconstitute the lyophilized EMAP-II protein in sterile, high-purity water (18MΩ-cm H₂O) to achieve an initial concentration of at least 100 µg/ml. This concentrated stock solution can then be further diluted to lower concentrations in other aqueous solutions as needed for your specific experimental requirements.

During reconstitution, use gentle mixing rather than vigorous vortexing. If the powder does not dissolve immediately, allow the mixture to incubate for 15-30 minutes with gentle agitation at room temperature. For particularly resistant samples, continue gentle mixing for up to 2 hours at room temperature.

Alternative Reconstitution Media

While sterile water is the standard reconstitution medium, you may alternatively reconstitute EMAP-II in 0.1% bovine serum albumin (BSA) aqueous buffer, which can provide additional protein stability during handling and storage.

Storage and Stability

Lyophilized Protein Storage

Store the unopened lyophilized powder desiccated below -18°C for long-term stability. The lyophilized form remains stable at room temperature for up to 3 weeks, though this should not be relied upon for extended storage.

Reconstituted Protein Storage

After reconstitution, store EMAP-II at 4°C for short-term use (2-7 days). For extended storage beyond one week, transfer the reconstituted protein to -18°C or preferably -20°C to -80°C. When storing reconstituted aliquots long-term, include a carrier protein to enhance stability.

Critical Handling Consideration

Avoid repeated freeze-thaw cycles, as these can compromise protein integrity and biological activity. Prepare working aliquots of appropriate size so you can use them without thawing the entire stock multiple times.

Quality Specifications

The recombinant human EMAP-II protein is typically produced in Escherichia coli as a non-glycosylated polypeptide chain containing 166 amino acids with a molecular mass of approximately 18.3 kDa. The purified product typically demonstrates greater than 98% purity as determined by reverse-phase high-performance liquid chromatography (RP-HPLC) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

Biological activity is conventionally assessed by measuring the apoptotic effect on MCF-7 cells at concentrations of 20-30 ng/ml.